###begin article-title 0
###xml 13 18 13 18 <italic xmlns:xlink="http://www.w3.org/1999/xlink">APOE </italic>
###xml 22 26 22 26 <italic xmlns:xlink="http://www.w3.org/1999/xlink">STH </italic>
Variation at APOE and STH loci and Alzheimer's disease
###end article-title 0
###begin p 1
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
###end p 1
###begin title 2
Background
###end title 2
###begin p 3
###xml 178 183 178 183 <italic xmlns:xlink="http://www.w3.org/1999/xlink">APOE </italic>
###xml 254 257 254 257 <italic xmlns:xlink="http://www.w3.org/1999/xlink">STH</italic>
###xml 387 392 387 392 <italic xmlns:xlink="http://www.w3.org/1999/xlink">APOE </italic>
###xml 412 416 412 416 <italic xmlns:xlink="http://www.w3.org/1999/xlink">STH </italic>
The apolipoprotein E (APOE) and tau proteins play important roles in the pathological development of Alzheimer's disease (AD). Many studies have shown an association between the APOE gene and AD. Association between AD and the newly discovered saitohin (STH) gene, nested within the intron of the tau gene, has been reported. The present study aimed to elucidate the association between APOE and AD, and between STH and AD in our sample.
###end p 3
###begin title 4
Methods
###end title 4
###begin p 5
###xml 58 63 58 63 <italic xmlns:xlink="http://www.w3.org/1999/xlink">APOE </italic>
###xml 95 102 95 96 <italic xmlns:xlink="http://www.w3.org/1999/xlink">&#949;</italic>
###xml 105 112 99 100 <italic xmlns:xlink="http://www.w3.org/1999/xlink">&#949;</italic>
###xml 119 126 107 108 <italic xmlns:xlink="http://www.w3.org/1999/xlink">&#949;</italic>
###xml 161 165 143 147 <italic xmlns:xlink="http://www.w3.org/1999/xlink">STH </italic>
###xml 193 201 <span type="species:ncbi:9606">patients</span>
The functional polymorphisms, rs429358 and rs7412, in the APOE gene (which together define the epsilon2, epsilon3, and epsilon4 alleles), and the Q7R SNP in the STH gene, were genotyped in 369 patients with AD and 289 healthy European-Americans. The associations between these two genes and AD were analyzed in a case-control design.
###end p 5
###begin title 6
Results
###end title 6
###begin p 7
###xml 68 80 68 74 <italic xmlns:xlink="http://www.w3.org/1999/xlink">APOE &#949;</italic>
###xml 90 97 84 85 <italic xmlns:xlink="http://www.w3.org/1999/xlink">&#949;</italic>
###xml 99 106 87 88 <italic xmlns:xlink="http://www.w3.org/1999/xlink">&#949;</italic>
###xml 121 128 103 104 <italic xmlns:xlink="http://www.w3.org/1999/xlink">&#949;</italic>
###xml 130 137 106 107 <italic xmlns:xlink="http://www.w3.org/1999/xlink">&#949;</italic>
###xml 205 212 175 176 <italic xmlns:xlink="http://www.w3.org/1999/xlink">&#949;</italic>
###xml 214 221 178 179 <italic xmlns:xlink="http://www.w3.org/1999/xlink">&#949;</italic>
###xml 342 349 300 301 <italic xmlns:xlink="http://www.w3.org/1999/xlink">&#949;</italic>
###xml 359 366 311 312 <italic xmlns:xlink="http://www.w3.org/1999/xlink">&#949;</italic>
###xml 376 383 322 323 <italic xmlns:xlink="http://www.w3.org/1999/xlink">&#949;</italic>
###xml 385 392 325 326 <italic xmlns:xlink="http://www.w3.org/1999/xlink">&#949;</italic>
###xml 407 414 341 342 <italic xmlns:xlink="http://www.w3.org/1999/xlink">&#949;</italic>
###xml 416 423 344 345 <italic xmlns:xlink="http://www.w3.org/1999/xlink">&#949;</italic>
###xml 517 518 439 440 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 523 528 445 450 <italic xmlns:xlink="http://www.w3.org/1999/xlink">APOE </italic>
###xml 597 604 519 520 <italic xmlns:xlink="http://www.w3.org/1999/xlink">&#949;</italic>
###xml 665 672 581 582 <italic xmlns:xlink="http://www.w3.org/1999/xlink">&#949;</italic>
###xml 677 684 587 588 <italic xmlns:xlink="http://www.w3.org/1999/xlink">&#949;</italic>
###xml 738 742 642 646 <italic xmlns:xlink="http://www.w3.org/1999/xlink">STH </italic>
Consistent with previously reported results, the frequencies of the APOE epsilon4 allele, epsilon4/epsilon4 genotype and epsilon3/epsilon4 genotype were significantly higher in AD cases than controls; the epsilon4/epsilon4 genotype frequency was significantly higher in early-onset AD (EOAD) than late-onset AD (LOAD); the frequencies of the epsilon2 allele, epsilon3 allele, epsilon3/epsilon3 genotype and epsilon2/epsilon3 genotype were significantly lower in AD cases than controls. Positive likelihood ratios (LRs+) of APOE alleles and genotypes increased in a linear trend with the number of epsilon4 alleles and decreased in a linear trend with the number of epsilon2 or epsilon3 alleles. There was no significant difference in the STH allele and genotype frequency distributions between AD cases and controls.
###end p 7
###begin title 8
Conclusion
###end title 8
###begin p 9
###xml 30 37 30 31 <italic xmlns:xlink="http://www.w3.org/1999/xlink">&#949;</italic>
###xml 92 99 86 87 <italic xmlns:xlink="http://www.w3.org/1999/xlink">&#949;</italic>
###xml 101 108 89 90 <italic xmlns:xlink="http://www.w3.org/1999/xlink">&#949;</italic>
###xml 205 212 187 188 <italic xmlns:xlink="http://www.w3.org/1999/xlink">&#949;</italic>
###xml 274 281 250 251 <italic xmlns:xlink="http://www.w3.org/1999/xlink">&#949;</italic>
###xml 368 375 338 339 <italic xmlns:xlink="http://www.w3.org/1999/xlink">&#949;</italic>
###xml 401 406 365 370 <italic xmlns:xlink="http://www.w3.org/1999/xlink">APOE </italic>
###xml 605 609 569 573 <italic xmlns:xlink="http://www.w3.org/1999/xlink">STH </italic>
This study confirmed that the epsilon4 allele is a dose-response risk factor for AD and the epsilon4/epsilon4 genotype was associated with a significantly earlier age of onset. Moreover, we found that the epsilon2 allele was a dose-response protective factor for AD and the epsilon3 allele exerted a weaker dose-response protective effect for risk of AD compared with epsilon2. In a clinical setting, APOE genotyping could offer additional biological evidence of whether a subject may develop AD, but it is not robust enough to serve as an independent screening or predictive test in the diagnosis of AD. STH variation was not significantly associated with AD in our sample.
###end p 9
###begin title 10
Background
###end title 10
###begin p 11
###xml 274 275 274 275 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B1">1</xref>
###xml 276 277 276 277 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B2">2</xref>
Alzheimer's disease (AD) is the most common cause of dementia. It is a primary neurodegenerative cerebral disease in the elderly, characterized by two major histopathologic changes in the brain, i.e., extracellular amyloid plaques and intracellular neurofibrillary tangles [1,2].
###end p 11
###begin p 12
###xml 176 179 176 179 <sup xmlns:xlink="http://www.w3.org/1999/xlink">th </sup>
###xml 186 189 186 189 <sup xmlns:xlink="http://www.w3.org/1999/xlink">th </sup>
###xml 234 235 234 235 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F1">1</xref>
###xml 576 577 576 577 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B3">3</xref>
###xml 797 798 797 798 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B4">4</xref>
###xml 997 1001 997 998 <italic xmlns:xlink="http://www.w3.org/1999/xlink">&#946;</italic>
###xml 1012 1016 1009 1010 <italic xmlns:xlink="http://www.w3.org/1999/xlink">&#946;</italic>
###xml 1061 1062 1055 1056 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B5">5</xref>
###xml 1110 1115 1104 1106 <italic xmlns:xlink="http://www.w3.org/1999/xlink">&#946; </italic>
###xml 1169 1174 1160 1162 <italic xmlns:xlink="http://www.w3.org/1999/xlink">&#946; </italic>
###xml 1189 1193 1177 1178 <italic xmlns:xlink="http://www.w3.org/1999/xlink">&#946;</italic>
###xml 1217 1218 1202 1203 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B6">6</xref>
Apolipoprotein E (APOE) is one of the major cholesterol transport proteins. It exists in three major isoforms, APOE2, APOE3 and APOE4. The three APOE isoforms differ in the 112th and 158th residues of their primary structures (Figure 1); these differences are classified as SNPs rs429358 and rs7412, respectively. The APOE3 protein has higher receptor affinity than the variant types APOE2 and APOE4. Substitution of the basic amino acid Arg158 in APOE3 by the neutral amino acid Cys158 in APOE2 results in the receptor affinity of APOE2 being reduced to 2% of that of APOE3 [3]. In the central nervous system, APOE mediates the uptake and redistribution of cholesterol, and different APOE isoforms modify cholesterol homeostasis by preferentially associating with specific lipoprotein particles [4]. The role of APOE in modifying cholesterol homeostasis in the brain may contribute to the relationship between APOE and AD. Furthermore, APOE exists inside the amyloid plaque, where it can bind to beta-amyloid (Abeta), which is a major component of the plaque [5]. Studies have shown that APOE interacts with Abeta to form a stable complex, altering the deposition of Abeta and affecting Abeta-induced neurotoxicity [6].
###end p 12
###begin p 13
###xml 0 5 0 5 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HhaI </italic>
###xml 31 36 31 36 <italic xmlns:xlink="http://www.w3.org/1999/xlink">APOE </italic>
###xml 46 48 46 48 <sup xmlns:xlink="http://www.w3.org/1999/xlink">1 </sup>
###xml 109 116 109 110 <italic xmlns:xlink="http://www.w3.org/1999/xlink">&#949;</italic>
###xml 205 212 197 198 <italic xmlns:xlink="http://www.w3.org/1999/xlink">&#949;</italic>
###xml 309 316 293 294 <italic xmlns:xlink="http://www.w3.org/1999/xlink">&#949;</italic>
HhaI cleavage sites within the APOE amplicon. 1 The residue positions are updated in the NCBI SNP database . epsilon2 allele (haplotype): 130Cys+176Cys (old:112Cys+158Cys) = 91bp+83 bp+others (</= 33 bp); epsilon3 allele (haplotype): 130Cys+176Arg (old:112Cys+158Arg) = 91 bp+ 48 bp+35 bp+others (</= 33 bp); epsilon4 allele (haplotype): 130Arg+176Arg (old:112Arg+ 158Arg) = 72+48+35+19+others (</= 33 bp).
###end p 13
###begin p 14
###xml 311 312 311 312 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B2">2</xref>
###xml 313 314 313 314 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B7">7</xref>
###xml 315 317 315 317 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B12">12</xref>
Moreover, APOE may be involved in Alzheimer's disease through a tau pathway. Studies have indicated that tau plays an important role in the physiopathology of Alzheimer's disease and that an extended haplotype (H1), covering the entire tau gene, including a 238 bp insertion in intron 9, is associated with AD [2,7-12], although these observations have not always been confirmed by other studies. APOE2 and APOE3 can bind to tau and prevent tau from being hyperphosphorylated. Although APOE4 also binds to tau, it cannot prevent tau from hyperphosphorylation, but destabilizes tau. The hyperphosphorylated tau can decrease tau's affinity for microtubules and severely disrupt microtubule stability, which has been postulated to be an important step in the formation of the paired helical filament (PHF) involved in neuronal degeneration. This may be part of the mechanism of APOE's important role in the etiology of AD.
###end p 14
###begin p 15
###xml 42 49 42 43 <italic xmlns:xlink="http://www.w3.org/1999/xlink">&#949;</italic>
###xml 52 59 46 47 <italic xmlns:xlink="http://www.w3.org/1999/xlink">&#949;</italic>
###xml 65 72 53 54 <italic xmlns:xlink="http://www.w3.org/1999/xlink">&#949;</italic>
###xml 97 99 79 81 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B13">13</xref>
###xml 189 196 171 172 <italic xmlns:xlink="http://www.w3.org/1999/xlink">&#949;</italic>
###xml 268 270 244 246 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B14">14</xref>
###xml 271 273 247 249 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B15">15</xref>
###xml 302 309 278 279 <italic xmlns:xlink="http://www.w3.org/1999/xlink">&#949;</italic>
###xml 370 377 340 341 <italic xmlns:xlink="http://www.w3.org/1999/xlink">&#949;</italic>
###xml 394 396 358 360 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B16">16</xref>
###xml 397 399 361 363 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B17">17</xref>
###xml 411 418 375 376 <italic xmlns:xlink="http://www.w3.org/1999/xlink">&#949;</italic>
###xml 484 486 442 444 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B18">18</xref>
###xml 487 489 445 447 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B20">20</xref>
###xml 501 508 459 460 <italic xmlns:xlink="http://www.w3.org/1999/xlink">&#949;</italic>
###xml 577 579 529 531 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B14">14</xref>
###xml 580 582 532 534 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B15">15</xref>
###xml 284 292 <span type="species:ncbi:9606">patients</span>
APOE2, APOE3 and APOE4 are encoded by the epsilon2, epsilon3 and epsilon4 alleles, respectively [13]. The roles of these alleles in modulating risk for AD have been widely studied. (a) The epsilon4 allele contributes to the risk for AD across most populations [e.g., [14,15]]. (b) AD patients with the epsilon4 allele have an earlier age-of-onset than those without the epsilon4 allele [e.g., [16,17]]. (c) The epsilon4 allele has a significant dose effect on the risk for AD [e.g., [18-20]]. (d) The epsilon2 allele may protect individuals from being affected with AD [e.g., [14,15]].
###end p 15
###begin p 16
###xml 10 13 10 13 <italic xmlns:xlink="http://www.w3.org/1999/xlink">STH</italic>
###xml 246 250 246 250 <italic xmlns:xlink="http://www.w3.org/1999/xlink">STH </italic>
###xml 380 384 380 384 <italic xmlns:xlink="http://www.w3.org/1999/xlink">STH </italic>
###xml 536 538 536 538 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B21">21</xref>
###xml 539 541 539 541 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B22">22</xref>
###xml 557 561 557 561 <italic xmlns:xlink="http://www.w3.org/1999/xlink">STH </italic>
###xml 615 619 615 619 <italic xmlns:xlink="http://www.w3.org/1999/xlink">STH </italic>
###xml 696 698 696 698 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B23">23</xref>
###xml 746 750 746 750 <italic xmlns:xlink="http://www.w3.org/1999/xlink">STH </italic>
###xml 792 796 792 796 <italic xmlns:xlink="http://www.w3.org/1999/xlink">STH </italic>
###xml 938 940 938 940 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B21">21</xref>
###xml 941 943 941 943 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B23">23</xref>
###xml 944 946 944 946 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B25">25</xref>
###xml 1000 1002 1000 1002 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B22">22</xref>
###xml 1003 1005 1003 1005 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B25">25</xref>
###xml 1006 1008 1006 1008 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B29">29</xref>
Saitohin (STH), an intronless gene, has been shown to be nested in the intron between exons 9 and 10 of the tau gene, 2.5 kb downstream from exon 9. This region is functionally critical due to the splicing of exon 10. The special location of the STH gene has prompted investigation into its possible role in AD and other neurodegenerative disorders. The A224G polymorphism in the STH gene, which causes a glutamine (Q) to arginine (R) substitution at residue 7 (Q7R), is in linkage disequilibrium with the extended tau H1/H2 haplotype [21,22]. That is, the STH Q allele is associated with tau haplotype H1, and the STH R allele is associated with haplotype H2. An initial study by Conrad et al. [23] demonstrated that the Q7R polymorphism in the STH gene was associated with risk for AD. The STH gene has also been associated with autosomal dominant frontotemporal dementia (FTD), progressive supranuclear palsy (PSP) and Pick's disease [21,23-25]. Nevertheless, these findings remain controversial [22,25-29].
###end p 16
###begin p 17
###xml 91 96 91 96 <italic xmlns:xlink="http://www.w3.org/1999/xlink">APOE </italic>
###xml 100 104 100 104 <italic xmlns:xlink="http://www.w3.org/1999/xlink">STH </italic>
###xml 219 224 219 224 <italic xmlns:xlink="http://www.w3.org/1999/xlink">APOE </italic>
The purpose of the present study was to elucidate the associations between the variants at APOE and STH loci and AD in our samples, and to explore the gene-dose effects and evaluate the implications of variation at the APOE gene in the diagnosis of AD.
###end p 17
###begin title 18
Methods and materials
###end title 18
###begin title 19
Subjects
###end title 19
###begin p 20
###xml 298 300 298 300 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B30">30</xref>
###xml 430 432 430 432 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B27">27</xref>
###xml 433 435 433 435 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B29">29</xref>
###xml 943 944 939 940 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 982 983 978 979 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-</sup>
###xml 1110 1112 1106 1108 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B31">31</xref>
###xml 1151 1153 1147 1149 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B32">32</xref>
###xml 58 66 <span type="species:ncbi:9606">patients</span>
###xml 735 743 <span type="species:ncbi:9606">patients</span>
The sample included 658 European-Americans, including 369 patients with AD and 289 healthy controls. The diagnosis of AD was based on criteria of the National Institute of Neurological and Communicative Disorders and Stroke and Alzheimer's disease and Related Disorders Association (NINCDS-ADRDA) [30]. The AD cases were divided into an early-onset (EOAD) group and a late-onset (LOAD) group based on an age-of-onset of 70 years [27,29]. Each subject was evaluated for an approximate date of AD onset, based on careful review of medical records and detailed interviews with one or more primary caregivers. The date of onset was operationally defined as the date at which the "earliest definite AD symptom" appeared. The mean age of AD patients was 73.6+/- 8.4 years (range: 51.8 to 92.7); the mean age-of-onset was 69.3+/- 8.3 years (range: 44.6 to 86.7; 3 subjects unknown); 143 were male, 226 were female; 180 had positive family history (FH+), 184 had negative family history (FH-), and 5 had unknown family history. Family history of AD was assessed using the Alzheimer Dementia Risk Questionnaire (ADRQ) [31] and the Dementia Questionnaire (DQ) [32]. Family history was considered positive if at least one first-degree relative met criteria for primary degenerative dementia. No cases suggestive of autosomal dominant transmission were identified.
###end p 20
###begin p 21
###xml 417 419 417 419 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B33">33</xref>
###xml 1366 1368 1362 1364 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B34">34</xref>
###xml 776 784 <span type="species:ncbi:9606">patients</span>
###xml 1593 1601 <span type="species:ncbi:9606">patients</span>
There were two sets of control subjects who were differentiated based on the method of ascertainment. The first set of healthy controls (n = 185) was recruited through advertisements in the community. They were screened using the Structured Clinical Interview for DSM-III-R (SCID), the Computerized Diagnostic Interview Schedule for DSM-III-R (C-DIS-R), the Schedule for Affective Disorders and Schizophrenia (SADS) [33], or an unstructured interview, to exclude major Axis I disorders, including substance dependence, psychotic disorders, mood disorders, anxiety disorders and dementia. Their mean age was 28.1+/- 9.1 years (range: 18.0 to 52.0); 81 were male and 104 were female. The second set of healthy controls (n = 104) was recruited primarily from among spouses of AD patients. Their mean age was 63.3+/- 16.3 years (range: 21.1 to 87.5); 49 were male and 55 were female. They were evaluated as being in generally good medical health for their age on the basis of a comprehensive evaluation that included medical history, physical and neurological examinations, serum chemistries, thyroid function studies, complete blood count, B12, folate, VDRL, urinalysis, electrocardiogram, and brain MRI or CT. The second set of controls was also required to have no significant evidence of cognitive impairment, as indicated by a Mini-Mental State Examination (MMSE) [34] score > 27. Subjects were recruited at Yale University School of Medicine, the University of Connecticut Health Center, or the VA Connecticut Healthcare System, West Haven Campus. Informed consent was obtained from all the patients and the controls. This study was performed after approval by the appropriate Institutional Review Boards (IRBs).
###end p 21
###begin title 22
Genotyping
###end title 22
###begin p 23
###xml 129 133 129 133 <italic xmlns:xlink="http://www.w3.org/1999/xlink">APOE</italic>
###xml 243 245 243 245 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B35">35</xref>
###xml 752 757 727 732 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HhaI </italic>
###xml 876 881 851 856 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HhaI </italic>
###xml 920 925 895 900 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HhaI </italic>
###xml 952 953 927 928 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F1">1</xref>
Genomic DNA was extracted from peripheral blood by standard methods. The region flanking the two target markers within exon 5 of APOE, rs429358 and rs7412, was amplified by a single polymerase chain reaction (PCR) using the following primers [35]: APOE-A: 5'-CGGGCACGGCTGTCCAAGGAG-3' and APOE-C: 5'-CACGCGGCCCTGTTCCACgAG-3' (g is mismatched). PCR was performed in a final volume of 10 mul with 1x PC2 buffer (Ab Peptides, Inc., St. Louis, MO), 1M betaine, 0.5 units of KlenTaq polymerase (Ab Peptides, Inc., St. Louis, MO) and 10 ng DNA. PCR conditions were set as follows: 95degreesC for 5 min; 35 cycles of 95degreesC for 30 s, 64degreesC for 30 s, and 72degreesC for 30 s. The genotypes were analyzed on 5% metaphor agarose gel after digestion with HhaI (New England Biolabs Inc., Beverly, MA). The size of the PCR product was 303 bp, within which there are eight constant HhaI cleavage sites (GCG|C) and two variant HhaI cleavage sites (see Figure 1).
###end p 23
###begin p 24
###xml 42 46 42 46 <italic xmlns:xlink="http://www.w3.org/1999/xlink">STH </italic>
###xml 131 133 131 133 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B23">23</xref>
###xml 476 482 451 457 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HinfI </italic>
###xml 606 612 581 587 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HinfI </italic>
The region flanking the Q7R marker in the STH gene was amplified by PCR using the primers from the initial study by Conrad et al. [23]. PCR was performed in a final volume of 15 mul with 1x PC2 buffer, 1M betaine, 0.75 units of KlenTaq polymerase and 25 ng DNA. PCR conditions were set as follows: 95degreesC for 5 min; 30 cycles of 95degreesC for 30 s, 60degreesC for 30 s, and 72degreesC for 30 s. The genotypes were analyzed on 3% metaphor agarose gel after digestion with HinfI (New England Biolabs Inc., Beverly, MA). The size of the PCR product was 226 bp. The R allele (Arginine, CGA) can be cut by HinfI (97 bp+74 bp+55 bp), whereas the Q allele (Glutamine, CAA) cannot (171 bp+55 bp).
###end p 24
###begin title 25
Statistical analysis
###end title 25
###begin p 26
###xml 168 174 168 170 <italic xmlns:xlink="http://www.w3.org/1999/xlink">&#945; </italic>
###xml 205 207 201 203 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B36">36</xref>
The comparisons in allele and genotype frequency distributions between two groups were performed with Fisher's exact test. Bonferroni correction was used to adjust the alpha level of multiple comparisons [36].
###end p 26
###begin p 27
###xml 68 70 68 70 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B37">37</xref>
###xml 73 79 73 79 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P(AD) </italic>
###xml 212 214 212 214 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B38">38</xref>
###xml 217 218 217 218 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 219 227 219 227 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Controls</italic>
###xml 245 246 233 234 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 247 249 235 237 <italic xmlns:xlink="http://www.w3.org/1999/xlink">AD</italic>
###xml 252 253 240 241 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 254 261 242 243 <italic xmlns:xlink="http://www.w3.org/1999/xlink">&#949;</italic>
###xml 262 264 244 246 <italic xmlns:xlink="http://www.w3.org/1999/xlink">AD</italic>
###xml 316 317 298 299 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 318 325 300 301 <italic xmlns:xlink="http://www.w3.org/1999/xlink">&#949;</italic>
###xml 326 334 302 310 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Controls</italic>
###xml 387 388 363 364 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 389 396 365 366 <italic xmlns:xlink="http://www.w3.org/1999/xlink">&#949;</italic>
###xml 397 399 367 369 <italic xmlns:xlink="http://www.w3.org/1999/xlink">AD</italic>
###xml 405 406 375 376 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 407 414 377 378 <italic xmlns:xlink="http://www.w3.org/1999/xlink">&#949;</italic>
###xml 415 423 379 387 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Controls</italic>
###xml 464 464 428 428 <inline-graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="1744-9081-2-13-i1.gif"/>
###xml 466 468 430 432 <italic xmlns:xlink="http://www.w3.org/1999/xlink">AD</italic>
###xml 469 476 433 434 <italic xmlns:xlink="http://www.w3.org/1999/xlink">&#949;</italic>
Positive predictive values (PPVs) were calculated with Bayes' rule [37]. P(AD) was the prior probability of developing AD, i.e., the prevalence of AD (see Formula). We used 15% as the estimated prevalence of AD [38]; P(Controls) approximately 1-P(AD); P(epsilon|AD) was allele or genotype frequency in AD cases, and P(epsilon|Controls) was allele or genotype frequency in controls. Both P(epsilon|AD) and P(epsilon|Controls) were estimated from the present study;  (AD|epsilon) was the posterior probability of developing AD given a certain allele or genotype.
###end p 27
###begin p 28
###xml 0 0 0 0 <inline-graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="1744-9081-2-13-i2.gif"/>

###end p 28
###begin p 29
###xml 31 32 31 32 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 131 133 131 133 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B39">39</xref>
###xml 173 180 173 174 <italic xmlns:xlink="http://www.w3.org/1999/xlink">&#949;</italic>
###xml 182 189 176 177 <italic xmlns:xlink="http://www.w3.org/1999/xlink">&#949;</italic>
###xml 255 257 243 245 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
Positive likelihood ratios (LRs+) were calculated by dividing the allele or genotype frequencies in AD cases by those in controls [39]. For example, if the frequency of the epsilon4/epsilon4 genotype is 0.139 in AD cases and 0.037 in controls, then the LR+ is equal to 0.139/0.037 = 3.757.
###end p 29
###begin p 30
###xml 23 28 23 28 <italic xmlns:xlink="http://www.w3.org/1999/xlink">APOE </italic>
###xml 99 104 99 104 <italic xmlns:xlink="http://www.w3.org/1999/xlink">APOE </italic>
###xml 185 187 185 187 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B40">40</xref>
###xml 230 235 230 235 <italic xmlns:xlink="http://www.w3.org/1999/xlink">APOE </italic>
###xml 256 258 256 258 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 385 390 385 390 <italic xmlns:xlink="http://www.w3.org/1999/xlink">APOE </italic>
The dose effect of the APOE gene, i.e., the relationship between the risk for AD and the number of APOE alleles, was tested by the chi-square test for trend using the software EPISTAT [40]. The relationships between the number of APOE alleles and their LRs+ were tested with Spearman's rank correlation analysis implemented in SPSS 13.0 (SPSS Inc., Chicago, IL). Gene dose effects for APOE were plotted using a polynomial curve-fitting plot method in S-PLUS 2000 (Mathsoft Engineering & Education, Inc., Cambridge, MA).
###end p 30
###begin p 31
###xml 230 235 230 235 <italic xmlns:xlink="http://www.w3.org/1999/xlink">APOE </italic>
###xml 239 243 239 243 <italic xmlns:xlink="http://www.w3.org/1999/xlink">STH </italic>
###xml 450 462 450 456 <italic xmlns:xlink="http://www.w3.org/1999/xlink">APOE &#949;</italic>
###xml 487 499 481 487 <italic xmlns:xlink="http://www.w3.org/1999/xlink">APOE &#949;</italic>
###xml 524 528 512 516 <italic xmlns:xlink="http://www.w3.org/1999/xlink">STH </italic>
###xml 563 567 551 555 <italic xmlns:xlink="http://www.w3.org/1999/xlink">STH </italic>
###xml 580 585 568 573 <italic xmlns:xlink="http://www.w3.org/1999/xlink">APOE </italic>
Age, sex, and AD family history are confounders that may cause false positive or false negative results. Thus, we used stepwise logistic regression analysis to investigate the association between the risk for AD and the number of APOE and STH alleles, controlling for the effects of the potential confounders. In the stepwise logistic regression model, the diagnosis served as the dependent variable; the independent variables included the number of APOE epsilon4 alleles, the number of APOE epsilon2 alleles, the number of STH R alleles, the interaction between STH R allele and APOE alleles, age, sex and AD family history. This analysis was performed with SPSS 13.0 software.
###end p 31
###begin title 32
Results
###end title 32
###begin p 33
###xml 123 128 123 128 <italic xmlns:xlink="http://www.w3.org/1999/xlink">APOE </italic>
###xml 132 136 132 136 <italic xmlns:xlink="http://www.w3.org/1999/xlink">STH </italic>
There was no significant difference in allele frequency distributions, genotype frequency distributions or dose effects of APOE and STH gene between our two sets of controls, so we combined the two control groups into one larger control group.
###end p 33
###begin title 34
###xml 16 21 16 21 <italic xmlns:xlink="http://www.w3.org/1999/xlink">APOE </italic>
Associations of APOE alleles and genotypes with Alzheimer's disease
###end title 34
###begin p 35
###xml 113 114 113 114 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T1">1</xref>
###xml 119 120 119 120 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T2">2</xref>
The comparisons of allele and genotype frequency distributions between AD cases and controls are shown in Tables 1 and 2. The genotype frequency distributions in both AD cases and controls were in Hardy-Weinberg equilibrium (HWE).
###end p 35
###begin p 36
###xml 39 44 39 44 <italic xmlns:xlink="http://www.w3.org/1999/xlink">APOE </italic>
###xml 48 52 48 52 <italic xmlns:xlink="http://www.w3.org/1999/xlink">STH </italic>
Distributions of allele frequencies of APOE and STH gene variations in European-American subjects
###end p 36
###begin p 37
###xml 0 434 0 428 <italic xmlns:xlink="http://www.w3.org/1999/xlink">f, frequency; n, number of alleles; N, number of individuals; 2N, number of chromosomes; AD, Alzheimer's disease; EOAD, early-onset AD (&#8804;70yrs); LOAD, late-onset AD (&gt;70yrs); Controls, the total controls combining two subgroups through two different diagnostic evaluations. The numbers in last column denote: 1. Comparing overall AD with controls (&#945; was set at 0.017 for each APOE allele comparison); 2. Comparing EOAD, LOAD, FH</italic>
###xml 434 435 428 429 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 435 444 429 438 <italic xmlns:xlink="http://www.w3.org/1999/xlink">AD and FH</italic>
###xml 444 445 438 439 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-</sup>
###xml 445 664 439 650 <italic xmlns:xlink="http://www.w3.org/1999/xlink">AD with controls respectively (&#945; was set at 0.003 for each APOE allele comparison); 3. Comparing male AD with male controls and female AD with female controls (&#945; was set at 0.003 for each APOE allele comparison)</italic>
f, frequency; n, number of alleles; N, number of individuals; 2N, number of chromosomes; AD, Alzheimer's disease; EOAD, early-onset AD (</=70yrs); LOAD, late-onset AD (>70yrs); Controls, the total controls combining two subgroups through two different diagnostic evaluations. The numbers in last column denote: 1. Comparing overall AD with controls (alpha was set at 0.017 for each APOE allele comparison); 2. Comparing EOAD, LOAD, FH+AD and FH-AD with controls respectively (alpha was set at 0.003 for each APOE allele comparison); 3. Comparing male AD with male controls and female AD with female controls (alpha was set at 0.003 for each APOE allele comparison).
###end p 37
###begin p 38
###xml 49 54 49 54 <italic xmlns:xlink="http://www.w3.org/1999/xlink">APOE </italic>
Distributions of the genotype frequencies of the APOE gene variations in European-American subjects
###end p 38
###begin p 39
###xml 0 358 0 330 <italic xmlns:xlink="http://www.w3.org/1999/xlink">f, N, AD, EOAD, LOAD, Controls and the comparing methods see Table 1. EOAD vs. LOAD, comparing EOAD and LOAD. &#945; was set at 0.010 (or 0.002) for each genotype comparison between overall AD and controls (or between AD subgroups and controls), referring to Table 1. &#949;2/&#949;3, the genotype consists of allele &#949;2 and allele &#949;3; as analogy</italic>
f, N, AD, EOAD, LOAD, Controls and the comparing methods see Table 1. EOAD vs. LOAD, comparing EOAD and LOAD. alpha was set at 0.010 (or 0.002) for each genotype comparison between overall AD and controls (or between AD subgroups and controls), referring to Table 1. epsilon2/epsilon3, the genotype consists of allele epsilon2 and allele epsilon3; as analogy.
###end p 39
###begin p 40
###xml 144 151 144 145 <italic xmlns:xlink="http://www.w3.org/1999/xlink">&#949;</italic>
###xml 161 168 155 156 <italic xmlns:xlink="http://www.w3.org/1999/xlink">&#949;</italic>
###xml 170 177 158 159 <italic xmlns:xlink="http://www.w3.org/1999/xlink">&#949;</italic>
###xml 183 190 165 166 <italic xmlns:xlink="http://www.w3.org/1999/xlink">&#949;</italic>
###xml 192 199 168 169 <italic xmlns:xlink="http://www.w3.org/1999/xlink">&#949;</italic>
###xml 293 300 263 264 <italic xmlns:xlink="http://www.w3.org/1999/xlink">&#949;</italic>
###xml 303 310 267 268 <italic xmlns:xlink="http://www.w3.org/1999/xlink">&#949;</italic>
###xml 321 328 279 280 <italic xmlns:xlink="http://www.w3.org/1999/xlink">&#949;</italic>
###xml 330 337 282 283 <italic xmlns:xlink="http://www.w3.org/1999/xlink">&#949;</italic>
###xml 343 350 289 290 <italic xmlns:xlink="http://www.w3.org/1999/xlink">&#949;</italic>
###xml 352 359 292 293 <italic xmlns:xlink="http://www.w3.org/1999/xlink">&#949;</italic>
The overall allele and genotype frequency distributions in AD cases were significantly different from those in controls. The frequencies of the epsilon4 allele, epsilon3/epsilon4 and epsilon4/epsilon4 genotypes were significantly higher in AD cases than in controls and the frequencies of the epsilon2, epsilon3 alleles, epsilon2/epsilon3 and epsilon3/epsilon3 genotypes were significantly lower in AD cases than in controls.
###end p 40
###begin p 41
###xml 80 82 80 82 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 88 90 88 90 <sup xmlns:xlink="http://www.w3.org/1999/xlink">- </sup>
###xml 312 319 312 313 <italic xmlns:xlink="http://www.w3.org/1999/xlink">&#949;</italic>
###xml 336 343 330 331 <italic xmlns:xlink="http://www.w3.org/1999/xlink">&#949;</italic>
###xml 345 352 333 334 <italic xmlns:xlink="http://www.w3.org/1999/xlink">&#949;</italic>
###xml 400 407 382 383 <italic xmlns:xlink="http://www.w3.org/1999/xlink">&#949;</italic>
###xml 409 416 385 386 <italic xmlns:xlink="http://www.w3.org/1999/xlink">&#949;</italic>
###xml 438 440 408 410 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 446 448 416 418 <sup xmlns:xlink="http://www.w3.org/1999/xlink">- </sup>
###xml 539 546 509 510 <italic xmlns:xlink="http://www.w3.org/1999/xlink">&#949;</italic>
###xml 563 570 527 528 <italic xmlns:xlink="http://www.w3.org/1999/xlink">&#949;</italic>
###xml 572 579 530 531 <italic xmlns:xlink="http://www.w3.org/1999/xlink">&#949;</italic>
###xml 627 634 579 580 <italic xmlns:xlink="http://www.w3.org/1999/xlink">&#949;</italic>
###xml 654 656 600 602 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 816 823 762 763 <italic xmlns:xlink="http://www.w3.org/1999/xlink">&#949;</italic>
###xml 825 832 765 766 <italic xmlns:xlink="http://www.w3.org/1999/xlink">&#949;</italic>
###xml 996 1003 930 931 <italic xmlns:xlink="http://www.w3.org/1999/xlink">&#949;</italic>
We also compared allele and genotype frequencies in AD subgroups (EOAD, LOAD, FH+ AD, FH- AD, male AD and female AD) with those in controls. The overall allele and genotype frequency distribution in each of the AD subgroups was significantly different from that in controls. Specifically, the frequencies of the epsilon4 allele and the epsilon3/epsilon4 genotype in each of the AD subgroups, and the epsilon4/epsilon4 genotype in EOAD, FH+ AD, FH- AD, and female AD were significantly higher than those in controls; the frequencies of the epsilon3 allele and the epsilon3/epsilon3 genotype in each of the AD subgroups, and the epsilon2 allele in EOAD, FH+ AD and female AD were significantly lower than those in controls. The genotype frequency distributions were significantly different between EOAD and LOAD [(the epsilon4/epsilon4 genotype frequency in EOAD (0.203) was significantly higher than that in LOAD (= 0.082)]. Among these differences, the nominal difference in the frequency of the epsilon2 allele between cases and controls was not statistically significant after Bonferroni correction.
###end p 41
###begin p 42
###xml 107 114 107 108 <italic xmlns:xlink="http://www.w3.org/1999/xlink">&#949;</italic>
###xml 120 127 114 115 <italic xmlns:xlink="http://www.w3.org/1999/xlink">&#949;</italic>
###xml 191 192 179 180 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 192 199 180 181 <italic xmlns:xlink="http://www.w3.org/1999/xlink">&#949;</italic>
###xml 192 201 180 183 <sub xmlns:xlink="http://www.w3.org/1999/xlink"><italic>&#949;</italic>4 </sub>
###xml 221 228 203 204 <italic xmlns:xlink="http://www.w3.org/1999/xlink">&#949;</italic>
###xml 221 230 203 206 <sub xmlns:xlink="http://www.w3.org/1999/xlink"><italic>&#949;</italic>4 </sub>
###xml 243 250 219 220 <italic xmlns:xlink="http://www.w3.org/1999/xlink">&#949;</italic>
###xml 243 251 219 221 <sub xmlns:xlink="http://www.w3.org/1999/xlink"><italic>&#949;</italic>4</sub>
###xml 264 265 234 235 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 265 272 235 236 <italic xmlns:xlink="http://www.w3.org/1999/xlink">&#949;</italic>
###xml 265 274 235 238 <sub xmlns:xlink="http://www.w3.org/1999/xlink"><italic>&#949;</italic>2 </sub>
###xml 294 301 258 259 <italic xmlns:xlink="http://www.w3.org/1999/xlink">&#949;</italic>
###xml 294 303 258 261 <sub xmlns:xlink="http://www.w3.org/1999/xlink"><italic>&#949;</italic>2 </sub>
###xml 316 323 274 275 <italic xmlns:xlink="http://www.w3.org/1999/xlink">&#949;</italic>
###xml 316 324 274 276 <sub xmlns:xlink="http://www.w3.org/1999/xlink"><italic>&#949;</italic>2</sub>
Stepwise logistic regression analyses showed that after adjusting for age, sex, and AD family history, the epsilon4 and epsilon2 alleles were still significantly associated with risk for AD (Pepsilon4 = 0.014, adjusted ORepsilon4 = 1.86,95% Clepsilon4: 1.13-3.05; Pepsilon2 = 0.041, adjusted ORepsilon2 = 0.36,95% Clepsilon2:0.13-0.96).
###end p 42
###begin title 43
###xml 21 26 21 26 <italic xmlns:xlink="http://www.w3.org/1999/xlink">APOE </italic>
PPVs and LRs+ of the APOE gene for the diagnosis of AD
###end title 43
###begin p 44
###xml 12 14 12 14 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 17 22 17 22 <italic xmlns:xlink="http://www.w3.org/1999/xlink">APOE </italic>
###xml 71 72 71 72 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T3">3</xref>
###xml 91 93 91 93 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 96 101 96 101 <italic xmlns:xlink="http://www.w3.org/1999/xlink">APOE </italic>
###xml 152 159 152 153 <italic xmlns:xlink="http://www.w3.org/1999/xlink">&#949;</italic>
###xml 161 168 155 156 <italic xmlns:xlink="http://www.w3.org/1999/xlink">&#949;</italic>
###xml 172 179 160 161 <italic xmlns:xlink="http://www.w3.org/1999/xlink">&#949;</italic>
###xml 183 190 165 166 <italic xmlns:xlink="http://www.w3.org/1999/xlink">&#949;</italic>
###xml 192 199 168 169 <italic xmlns:xlink="http://www.w3.org/1999/xlink">&#949;</italic>
###xml 203 210 173 174 <italic xmlns:xlink="http://www.w3.org/1999/xlink">&#949;</italic>
###xml 214 221 178 179 <italic xmlns:xlink="http://www.w3.org/1999/xlink">&#949;</italic>
###xml 223 230 181 182 <italic xmlns:xlink="http://www.w3.org/1999/xlink">&#949;</italic>
###xml 234 241 186 187 <italic xmlns:xlink="http://www.w3.org/1999/xlink">&#949;</italic>
###xml 243 250 189 190 <italic xmlns:xlink="http://www.w3.org/1999/xlink">&#949;</italic>
###xml 254 261 194 195 <italic xmlns:xlink="http://www.w3.org/1999/xlink">&#949;</italic>
###xml 265 272 199 200 <italic xmlns:xlink="http://www.w3.org/1999/xlink">&#949;</italic>
###xml 274 281 202 203 <italic xmlns:xlink="http://www.w3.org/1999/xlink">&#949;</italic>
PPVs and LRs+ of APOE alleles and genotypes for AD are listed in Table 3. Both PPVs and LRs+ of APOE alleles and genotypes were in the following order: epsilon4/epsilon4 > epsilon4 > epsilon3/epsilon4 > epsilon3 > epsilon2/epsilon4 > epsilon3/epsilon3 > epsilon2 > epsilon2/epsilon3.
###end p 44
###begin p 45
###xml 30 32 30 32 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 35 40 35 40 <italic xmlns:xlink="http://www.w3.org/1999/xlink">APOE </italic>
Interpretation of PPVs and LRs+ of APOE alleles and genotypes
###end p 45
###begin p 46
###xml 0 44 0 44 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PPV, estimated positive predictive value; LR</italic>
###xml 44 45 44 45 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 45 73 45 73 <italic xmlns:xlink="http://www.w3.org/1999/xlink">, positive likelihood ratios</italic>
###xml 0 3 <span type="species:ncbi:10796?0.09130166563849476|species:ncbi:12211?0.07279457125231338">PPV</span>
PPV, estimated positive predictive value; LR+, positive likelihood ratios.
###end p 46
###begin p 47
###xml 0 1 0 1 <sup xmlns:xlink="http://www.w3.org/1999/xlink">1</sup>
###xml 1 18 1 18 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Reference to [39]</italic>
1Reference to [39].
###end p 47
###begin p 48
###xml 64 71 64 65 <italic xmlns:xlink="http://www.w3.org/1999/xlink">&#949;</italic>
###xml 73 80 67 68 <italic xmlns:xlink="http://www.w3.org/1999/xlink">&#949;</italic>
###xml 190 192 178 180 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 218 220 206 208 <sup xmlns:xlink="http://www.w3.org/1999/xlink">- </sup>
###xml 254 261 242 243 <italic xmlns:xlink="http://www.w3.org/1999/xlink">&#949;</italic>
###xml 263 270 245 246 <italic xmlns:xlink="http://www.w3.org/1999/xlink">&#949;</italic>
###xml 362 364 338 340 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 375 382 351 352 <italic xmlns:xlink="http://www.w3.org/1999/xlink">&#949;</italic>
###xml 399 406 369 370 <italic xmlns:xlink="http://www.w3.org/1999/xlink">&#949;</italic>
###xml 408 415 372 373 <italic xmlns:xlink="http://www.w3.org/1999/xlink">&#949;</italic>
###xml 464 466 422 424 <sup xmlns:xlink="http://www.w3.org/1999/xlink">- </sup>
###xml 242 245 <span type="species:ncbi:10796?0.09130166563849476|species:ncbi:12211?0.07279457125231338">PPV</span>
We also compared PPVs for different subtypes of AD. PPVs of the epsilon4/epsilon4 genotype were much higher in EOAD (49.2% vs. 28.1% for LOAD), female AD (48.4% vs. 28.9% for male AD) and FH+ AD (43.6% vs. 36.8% for FH- AD). In addition, the PPV for the epsilon3/epsilon4 genotype was higher in LOAD (31.1%) than EOAD (26.0%). Finally, the PPVs were lower for FH+ AD for the epsilon2 allele and the epsilon2/epsilon3 genotype (3.9%, 4.6%, respectively) than for FH- AD (8.0%, 6.1%, respectively).
###end p 48
###begin title 49
###xml 25 30 25 30 <italic xmlns:xlink="http://www.w3.org/1999/xlink">APOE </italic>
###xml 61 62 61 62 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T4">4</xref>
###xml 74 75 74 75 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F2">2</xref>
Gene dose effects of the APOE gene on the risk for AD (Table 4 and Figure 2)
###end title 49
###begin p 50
###xml 65 70 65 70 <italic xmlns:xlink="http://www.w3.org/1999/xlink">APOE </italic>
Distributions of the frequencies of the genotypes with ascending APOE allele number
###end p 50
###begin p 51
f, N, AD, EOAD, LOAD, Controls, and the comparing methods see Tables 1 and 2.
###end p 51
###begin p 52
###xml 0 6 0 2 <italic xmlns:xlink="http://www.w3.org/1999/xlink">&#945; </italic>
alpha was set at 0.017 (or 0.003) for each Chi-Square test for trend analysis in overall AD (or AD subgroups), referring to Tables 1 and 2.
###end p 52
###begin p 53
###xml 16 21 16 21 <italic xmlns:xlink="http://www.w3.org/1999/xlink">APOE </italic>
###xml 76 83 76 77 <italic xmlns:xlink="http://www.w3.org/1999/xlink">&#949;</italic>
###xml 104 111 98 99 <italic xmlns:xlink="http://www.w3.org/1999/xlink">&#949;</italic>
###xml 133 140 121 122 <italic xmlns:xlink="http://www.w3.org/1999/xlink">&#949;</italic>
Dose effects of APOE gene alleles. X-axis represents the copies of alleles (epsilon2 allele, pink line; epsilon3 allele, green line; epsilon4 allele, red line); Y-axis represents the positive likelihood ratios of genotype frequency (in AD cases vs. in Controls)
###end p 53
###begin p 54
###xml 118 125 118 119 <italic xmlns:xlink="http://www.w3.org/1999/xlink">&#949;</italic>
###xml 212 219 206 207 <italic xmlns:xlink="http://www.w3.org/1999/xlink">&#949;</italic>
###xml 224 231 212 213 <italic xmlns:xlink="http://www.w3.org/1999/xlink">&#949;</italic>
The chi-square test for trend analyses showed that there was a significant positive correlation between the number of epsilon4 alleles and risk for AD and a significant negative correlation between the number of epsilon2 or epsilon3 alleles and risk for AD.
###end p 54
###begin p 55
###xml 78 83 78 83 <italic xmlns:xlink="http://www.w3.org/1999/xlink">APOE </italic>
###xml 127 128 127 128 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 178 185 178 179 <italic xmlns:xlink="http://www.w3.org/1999/xlink">&#949;</italic>
###xml 221 228 215 216 <italic xmlns:xlink="http://www.w3.org/1999/xlink">&#949;</italic>
###xml 221 230 215 218 <sub xmlns:xlink="http://www.w3.org/1999/xlink"><italic>&#949;</italic>4 </sub>
###xml 245 252 233 234 <italic xmlns:xlink="http://www.w3.org/1999/xlink">&#949;</italic>
###xml 245 254 233 236 <sub xmlns:xlink="http://www.w3.org/1999/xlink"><italic>&#949;</italic>4 </sub>
###xml 305 312 287 288 <italic xmlns:xlink="http://www.w3.org/1999/xlink">&#949;</italic>
###xml 317 324 293 294 <italic xmlns:xlink="http://www.w3.org/1999/xlink">&#949;</italic>
###xml 360 367 330 331 <italic xmlns:xlink="http://www.w3.org/1999/xlink">&#949;</italic>
###xml 372 379 336 337 <italic xmlns:xlink="http://www.w3.org/1999/xlink">&#949;</italic>
###xml 360 381 330 339 <sub xmlns:xlink="http://www.w3.org/1999/xlink"><italic>&#949;</italic>2 or <italic>&#949;</italic>3 </sub>
###xml 395 402 353 354 <italic xmlns:xlink="http://www.w3.org/1999/xlink">&#949;</italic>
###xml 395 404 353 356 <sub xmlns:xlink="http://www.w3.org/1999/xlink"><italic>&#949;</italic>2 </sub>
###xml 421 428 373 374 <italic xmlns:xlink="http://www.w3.org/1999/xlink">&#949;</italic>
###xml 421 430 373 376 <sub xmlns:xlink="http://www.w3.org/1999/xlink"><italic>&#949;</italic>3 </sub>
Similarly, the Spearman's rank correlation analysis showed that the number of APOE alleles was significantly correlated with LR+, which increased linearly with the number of the epsilon4 alleles (correlation coefficient repsilon4 = 1.0; slope K epsilon4 = 1.602) and decreased linearly with the number of epsilon2 or epsilon3 alleles (correlation coefficient repsilon2 or epsilon3 = 1.0; slope Kepsilon2 = -0.543; slope Kepsilon3 = -1.122).
###end p 55
###begin title 56
###xml 19 23 19 23 <italic xmlns:xlink="http://www.w3.org/1999/xlink">STH </italic>
Association of the STH gene with AD
###end title 56
###begin p 57
###xml 29 33 29 33 <italic xmlns:xlink="http://www.w3.org/1999/xlink">STH </italic>
###xml 172 177 172 177 <italic xmlns:xlink="http://www.w3.org/1999/xlink">APOE </italic>
###xml 267 271 267 271 <italic xmlns:xlink="http://www.w3.org/1999/xlink">STH </italic>
No significant difference in STH allele and genotype frequency distributions was found between AD cases and controls. Even after adjusting for potential confounding by the APOE gene, age, sex and AD family history, stepwise logistic analyses showed no association of STH alleles or genotypes with AD.
###end p 57
###begin title 58
###xml 32 36 32 36 <italic xmlns:xlink="http://www.w3.org/1999/xlink">STH </italic>
###xml 49 54 49 54 <italic xmlns:xlink="http://www.w3.org/1999/xlink">APOE </italic>
Interactive effects between the STH gene and the APOE gene
###end title 58
###begin p 59
###xml 6 10 6 10 <italic xmlns:xlink="http://www.w3.org/1999/xlink">STH </italic>
###xml 89 94 89 94 <italic xmlns:xlink="http://www.w3.org/1999/xlink">APOE </italic>
Using STH genotypes, we grouped all subjects into QQ, RR and QR groups. We then compared APOE allele and genotype frequency distributions in these three groups in both cases and controls. No significant difference was found for any of the comparisons (data not shown).
###end p 59
###begin title 60
Discussion
###end title 60
###begin p 61
###xml 73 78 73 78 <italic xmlns:xlink="http://www.w3.org/1999/xlink">APOE </italic>
###xml 101 106 101 106 <italic xmlns:xlink="http://www.w3.org/1999/xlink">APOE </italic>
###xml 115 122 115 116 <italic xmlns:xlink="http://www.w3.org/1999/xlink">&#949;</italic>
###xml 125 132 119 120 <italic xmlns:xlink="http://www.w3.org/1999/xlink">&#949;</italic>
###xml 138 145 126 127 <italic xmlns:xlink="http://www.w3.org/1999/xlink">&#949;</italic>
###xml 377 382 359 364 <italic xmlns:xlink="http://www.w3.org/1999/xlink">APOE </italic>
The present study confirmed the well-established association between the APOE gene and AD. All three APOE alleles (epsilon2, epsilon3 and epsilon4) showed dose effects on the risk for AD, and followed a co-dominant mode of inheritance. We also examined, for the first time to our knowledge for a trait in neuropsychiatry, a mathematical measure of the predictive value of each APOE allele and genotype for AD diagnosis risk.
###end p 61
###begin p 62
###xml 53 58 53 58 <italic xmlns:xlink="http://www.w3.org/1999/xlink">APOE </italic>
###xml 196 203 196 197 <italic xmlns:xlink="http://www.w3.org/1999/xlink">&#949;</italic>
###xml 217 224 211 212 <italic xmlns:xlink="http://www.w3.org/1999/xlink">&#949;</italic>
###xml 226 233 214 215 <italic xmlns:xlink="http://www.w3.org/1999/xlink">&#949;</italic>
###xml 252 259 234 235 <italic xmlns:xlink="http://www.w3.org/1999/xlink">&#949;</italic>
###xml 261 268 237 238 <italic xmlns:xlink="http://www.w3.org/1999/xlink">&#949;</italic>
###xml 309 316 279 280 <italic xmlns:xlink="http://www.w3.org/1999/xlink">&#949;</italic>
###xml 330 337 294 295 <italic xmlns:xlink="http://www.w3.org/1999/xlink">&#949;</italic>
###xml 351 358 309 310 <italic xmlns:xlink="http://www.w3.org/1999/xlink">&#949;</italic>
###xml 360 367 312 313 <italic xmlns:xlink="http://www.w3.org/1999/xlink">&#949;</italic>
###xml 386 393 332 333 <italic xmlns:xlink="http://www.w3.org/1999/xlink">&#949;</italic>
###xml 395 402 335 336 <italic xmlns:xlink="http://www.w3.org/1999/xlink">&#949;</italic>
###xml 519 521 453 455 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B14">14</xref>
###xml 522 524 456 458 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B15">15</xref>
###xml 596 603 530 531 <italic xmlns:xlink="http://www.w3.org/1999/xlink">&#949;</italic>
###xml 605 612 533 534 <italic xmlns:xlink="http://www.w3.org/1999/xlink">&#949;</italic>
###xml 713 720 635 636 <italic xmlns:xlink="http://www.w3.org/1999/xlink">&#949;</italic>
###xml 722 729 638 639 <italic xmlns:xlink="http://www.w3.org/1999/xlink">&#949;</italic>
###xml 841 843 751 753 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B19">19</xref>
In addition to a significant association between the APOE gene and Alzheimer's disease, subgroup analyses revealed an association with subtypes based on age of onset, family history, and sex. The epsilon4 allele, the epsilon4/epsilon4 genotype and the epsilon3/epsilon4 genotype were risk factors for AD; the epsilon2 allele, the epsilon3 allele, the epsilon2/epsilon3 genotype and the epsilon3/epsilon3 genotype were protective factors for AD. These findings are consistent with those in most previous studies [e.g., [14,15]]. Further comparisons among AD subgroups and controls showed that the epsilon4/epsilon4 genotype frequency was significantly higher in EOAD than in LOAD and controls, suggesting that the epsilon4/epsilon4 genotype can significantly reduce the age-of-onset. This is consistent with findings in other studies [e.g., [19]].
###end p 62
###begin p 63
###xml 34 41 34 35 <italic xmlns:xlink="http://www.w3.org/1999/xlink">&#949;</italic>
###xml 43 50 37 38 <italic xmlns:xlink="http://www.w3.org/1999/xlink">&#949;</italic>
###xml 141 148 129 130 <italic xmlns:xlink="http://www.w3.org/1999/xlink">&#949;</italic>
###xml 150 157 132 133 <italic xmlns:xlink="http://www.w3.org/1999/xlink">&#949;</italic>
###xml 323 330 299 300 <italic xmlns:xlink="http://www.w3.org/1999/xlink">&#949;</italic>
###xml 332 339 302 303 <italic xmlns:xlink="http://www.w3.org/1999/xlink">&#949;</italic>
###xml 464 466 428 430 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B41">41</xref>
###xml 467 469 431 433 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B43">43</xref>
###xml 23 26 <span type="species:ncbi:10796?0.09130166563849476|species:ncbi:12211?0.07279457125231338">PPV</span>
We also found that the PPV of the epsilon4/epsilon4 genotype was significantly higher in females (48.4%) than in males (28.9%). Although the epsilon4/epsilon4 genotype frequency in female AD cases was significantly higher than in female controls, we found no significant difference in males. These results suggest that the epsilon4/epsilon4 genotype is a stronger risk factor for females than for males. This is consistent with findings from other studies [e.g., [41-43]]. However since sex distributions were not well matched between cases and controls, it could also reflect a stratification effect by sex.
###end p 63
###begin p 64
###xml 136 143 136 137 <italic xmlns:xlink="http://www.w3.org/1999/xlink">&#949;</italic>
###xml 219 221 213 215 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B18">18</xref>
###xml 297 304 291 292 <italic xmlns:xlink="http://www.w3.org/1999/xlink">&#949;</italic>
###xml 309 316 297 298 <italic xmlns:xlink="http://www.w3.org/1999/xlink">&#949;</italic>
###xml 352 357 334 339 <italic xmlns:xlink="http://www.w3.org/1999/xlink">APOE </italic>
###xml 391 392 373 374 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
Both the chi-square test for trend and the regression analyses revealed that the risk for AD increased significantly with the number of epsilon4 alleles. This is also consistent with findings from other studies [e.g., [18]]. In addition, we found that the risk for AD decreased with the number of epsilon2 or epsilon3 alleles. Furthermore, the dose of APOE alleles was linearly related to LR+. These results are all compatible with those from our allelewise analyses.
###end p 64
###begin p 65
###xml 120 127 120 121 <italic xmlns:xlink="http://www.w3.org/1999/xlink">&#949;</italic>
###xml 181 188 175 176 <italic xmlns:xlink="http://www.w3.org/1999/xlink">&#949;</italic>
###xml 266 273 254 255 <italic xmlns:xlink="http://www.w3.org/1999/xlink">&#949;</italic>
###xml 279 286 261 262 <italic xmlns:xlink="http://www.w3.org/1999/xlink">&#949;</italic>
###xml 414 421 390 391 <italic xmlns:xlink="http://www.w3.org/1999/xlink">&#949;</italic>
###xml 423 430 393 394 <italic xmlns:xlink="http://www.w3.org/1999/xlink">&#949;</italic>
###xml 470 472 434 436 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 527 534 491 492 <italic xmlns:xlink="http://www.w3.org/1999/xlink">&#949;</italic>
###xml 623 630 581 582 <italic xmlns:xlink="http://www.w3.org/1999/xlink">&#949;</italic>
###xml 647 654 599 600 <italic xmlns:xlink="http://www.w3.org/1999/xlink">&#949;</italic>
###xml 733 740 679 680 <italic xmlns:xlink="http://www.w3.org/1999/xlink">&#949;</italic>
###xml 757 764 697 698 <italic xmlns:xlink="http://www.w3.org/1999/xlink">&#949;</italic>
###xml 850 852 784 786 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 862 864 796 798 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B39">39</xref>
###xml 883 888 817 822 <italic xmlns:xlink="http://www.w3.org/1999/xlink">APOE </italic>
###xml 1004 1009 938 943 <italic xmlns:xlink="http://www.w3.org/1999/xlink">APOE </italic>
###xml 1181 1183 1115 1117 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B44">44</xref>
###xml 1250 1252 1184 1186 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 1255 1260 1189 1194 <italic xmlns:xlink="http://www.w3.org/1999/xlink">APOE </italic>
###xml 1319 1326 1253 1254 <italic xmlns:xlink="http://www.w3.org/1999/xlink">&#949;</italic>
###xml 1328 1335 1256 1257 <italic xmlns:xlink="http://www.w3.org/1999/xlink">&#949;</italic>
###xml 1339 1346 1261 1262 <italic xmlns:xlink="http://www.w3.org/1999/xlink">&#949;</italic>
###xml 1350 1357 1266 1267 <italic xmlns:xlink="http://www.w3.org/1999/xlink">&#949;</italic>
###xml 1359 1366 1269 1270 <italic xmlns:xlink="http://www.w3.org/1999/xlink">&#949;</italic>
###xml 1370 1377 1274 1275 <italic xmlns:xlink="http://www.w3.org/1999/xlink">&#949;</italic>
###xml 1381 1388 1279 1280 <italic xmlns:xlink="http://www.w3.org/1999/xlink">&#949;</italic>
###xml 1390 1397 1282 1283 <italic xmlns:xlink="http://www.w3.org/1999/xlink">&#949;</italic>
###xml 1401 1408 1287 1288 <italic xmlns:xlink="http://www.w3.org/1999/xlink">&#949;</italic>
###xml 1410 1417 1290 1291 <italic xmlns:xlink="http://www.w3.org/1999/xlink">&#949;</italic>
###xml 1421 1428 1295 1296 <italic xmlns:xlink="http://www.w3.org/1999/xlink">&#949;</italic>
###xml 1432 1439 1300 1301 <italic xmlns:xlink="http://www.w3.org/1999/xlink">&#949;</italic>
###xml 1441 1448 1303 1304 <italic xmlns:xlink="http://www.w3.org/1999/xlink">&#949;</italic>
###xml 1461 1462 1317 1318 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T3">3</xref>
###xml 1492 1499 1348 1349 <italic xmlns:xlink="http://www.w3.org/1999/xlink">&#949;</italic>
###xml 1501 1508 1351 1352 <italic xmlns:xlink="http://www.w3.org/1999/xlink">&#949;</italic>
###xml 1512 1519 1356 1357 <italic xmlns:xlink="http://www.w3.org/1999/xlink">&#949;</italic>
###xml 1583 1590 1421 1422 <italic xmlns:xlink="http://www.w3.org/1999/xlink">&#949;</italic>
###xml 1605 1612 1437 1438 <italic xmlns:xlink="http://www.w3.org/1999/xlink">&#949;</italic>
###xml 1616 1623 1442 1443 <italic xmlns:xlink="http://www.w3.org/1999/xlink">&#949;</italic>
###xml 1625 1632 1445 1446 <italic xmlns:xlink="http://www.w3.org/1999/xlink">&#949;</italic>
###xml 1638 1645 1452 1453 <italic xmlns:xlink="http://www.w3.org/1999/xlink">&#949;</italic>
###xml 1647 1654 1455 1456 <italic xmlns:xlink="http://www.w3.org/1999/xlink">&#949;</italic>
###xml 1704 1711 1506 1507 <italic xmlns:xlink="http://www.w3.org/1999/xlink">&#949;</italic>
###xml 1760 1767 1556 1557 <italic xmlns:xlink="http://www.w3.org/1999/xlink">&#949;</italic>
###xml 1806 1813 1596 1597 <italic xmlns:xlink="http://www.w3.org/1999/xlink">&#949;</italic>
###xml 1849 1856 1633 1634 <italic xmlns:xlink="http://www.w3.org/1999/xlink">&#949;</italic>
###xml 1863 1870 1641 1642 <italic xmlns:xlink="http://www.w3.org/1999/xlink">&#949;</italic>
###xml 1872 1879 1644 1645 <italic xmlns:xlink="http://www.w3.org/1999/xlink">&#949;</italic>
###xml 1882 1889 1648 1649 <italic xmlns:xlink="http://www.w3.org/1999/xlink">&#949;</italic>
###xml 1963 1970 1723 1724 <italic xmlns:xlink="http://www.w3.org/1999/xlink">&#949;</italic>
###xml 1985 1992 1739 1740 <italic xmlns:xlink="http://www.w3.org/1999/xlink">&#949;</italic>
###xml 1996 2003 1744 1745 <italic xmlns:xlink="http://www.w3.org/1999/xlink">&#949;</italic>
###xml 2005 2012 1747 1748 <italic xmlns:xlink="http://www.w3.org/1999/xlink">&#949;</italic>
###xml 2018 2025 1754 1755 <italic xmlns:xlink="http://www.w3.org/1999/xlink">&#949;</italic>
###xml 2029 2036 1759 1760 <italic xmlns:xlink="http://www.w3.org/1999/xlink">&#949;</italic>
###xml 2038 2045 1762 1763 <italic xmlns:xlink="http://www.w3.org/1999/xlink">&#949;</italic>
###xml 2233 2240 1951 1952 <italic xmlns:xlink="http://www.w3.org/1999/xlink">&#949;</italic>
###xml 2244 2251 1956 1957 <italic xmlns:xlink="http://www.w3.org/1999/xlink">&#949;</italic>
###xml 2257 2264 1963 1964 <italic xmlns:xlink="http://www.w3.org/1999/xlink">&#949;</italic>
###xml 2266 2273 1966 1967 <italic xmlns:xlink="http://www.w3.org/1999/xlink">&#949;</italic>
###xml 2277 2284 1971 1972 <italic xmlns:xlink="http://www.w3.org/1999/xlink">&#949;</italic>
###xml 2286 2293 1974 1975 <italic xmlns:xlink="http://www.w3.org/1999/xlink">&#949;</italic>
###xml 2316 2323 1998 1999 <italic xmlns:xlink="http://www.w3.org/1999/xlink">&#949;</italic>
###xml 2380 2387 2056 2057 <italic xmlns:xlink="http://www.w3.org/1999/xlink">&#949;</italic>
###xml 2497 2498 2167 2168 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F2">2</xref>
###xml 2509 2516 2179 2180 <italic xmlns:xlink="http://www.w3.org/1999/xlink">&#949;</italic>
###xml 2518 2525 2182 2183 <italic xmlns:xlink="http://www.w3.org/1999/xlink">&#949;</italic>
###xml 2559 2566 2217 2218 <italic xmlns:xlink="http://www.w3.org/1999/xlink">&#949;</italic>
###xml 2568 2575 2220 2221 <italic xmlns:xlink="http://www.w3.org/1999/xlink">&#949;</italic>
###xml 2578 2585 2224 2225 <italic xmlns:xlink="http://www.w3.org/1999/xlink">&#949;</italic>
###xml 2587 2594 2227 2228 <italic xmlns:xlink="http://www.w3.org/1999/xlink">&#949;</italic>
###xml 2597 2604 2231 2232 <italic xmlns:xlink="http://www.w3.org/1999/xlink">&#949;</italic>
###xml 2658 2665 2286 2287 <italic xmlns:xlink="http://www.w3.org/1999/xlink">&#949;</italic>
###xml 2672 2679 2294 2295 <italic xmlns:xlink="http://www.w3.org/1999/xlink">&#949;</italic>
###xml 2721 2728 2337 2338 <italic xmlns:xlink="http://www.w3.org/1999/xlink">&#949;</italic>
###xml 2781 2788 2391 2392 <italic xmlns:xlink="http://www.w3.org/1999/xlink">&#949;</italic>
###xml 2795 2802 2399 2400 <italic xmlns:xlink="http://www.w3.org/1999/xlink">&#949;</italic>
###xml 2870 2877 2468 2469 <italic xmlns:xlink="http://www.w3.org/1999/xlink">&#949;</italic>
###xml 2879 2886 2471 2472 <italic xmlns:xlink="http://www.w3.org/1999/xlink">&#949;</italic>
###xml 2921 2928 2507 2508 <italic xmlns:xlink="http://www.w3.org/1999/xlink">&#949;</italic>
###xml 2930 2937 2510 2511 <italic xmlns:xlink="http://www.w3.org/1999/xlink">&#949;</italic>
###xml 2999 3006 2573 2574 <italic xmlns:xlink="http://www.w3.org/1999/xlink">&#949;</italic>
###xml 3008 3015 2576 2577 <italic xmlns:xlink="http://www.w3.org/1999/xlink">&#949;</italic>
###xml 3019 3026 2581 2582 <italic xmlns:xlink="http://www.w3.org/1999/xlink">&#949;</italic>
###xml 3030 3037 2586 2587 <italic xmlns:xlink="http://www.w3.org/1999/xlink">&#949;</italic>
###xml 3039 3046 2589 2590 <italic xmlns:xlink="http://www.w3.org/1999/xlink">&#949;</italic>
###xml 3122 3129 2666 2667 <italic xmlns:xlink="http://www.w3.org/1999/xlink">&#949;</italic>
###xml 3136 3143 2674 2675 <italic xmlns:xlink="http://www.w3.org/1999/xlink">&#949;</italic>
###xml 3185 3192 2717 2718 <italic xmlns:xlink="http://www.w3.org/1999/xlink">&#949;</italic>
###xml 3208 3215 2734 2735 <italic xmlns:xlink="http://www.w3.org/1999/xlink">&#949;</italic>
###xml 3217 3224 2737 2738 <italic xmlns:xlink="http://www.w3.org/1999/xlink">&#949;</italic>
###xml 3230 3237 2744 2745 <italic xmlns:xlink="http://www.w3.org/1999/xlink">&#949;</italic>
###xml 3239 3246 2747 2748 <italic xmlns:xlink="http://www.w3.org/1999/xlink">&#949;</italic>
###xml 3288 3295 2790 2791 <italic xmlns:xlink="http://www.w3.org/1999/xlink">&#949;</italic>
###xml 3302 3309 2798 2799 <italic xmlns:xlink="http://www.w3.org/1999/xlink">&#949;</italic>
###xml 3332 3339 2822 2823 <italic xmlns:xlink="http://www.w3.org/1999/xlink">&#949;</italic>
###xml 3341 3348 2825 2826 <italic xmlns:xlink="http://www.w3.org/1999/xlink">&#949;</italic>
###xml 3436 3443 2914 2915 <italic xmlns:xlink="http://www.w3.org/1999/xlink">&#949;</italic>
###xml 3495 3502 2967 2968 <italic xmlns:xlink="http://www.w3.org/1999/xlink">&#949;</italic>
###xml 3546 3553 3012 3013 <italic xmlns:xlink="http://www.w3.org/1999/xlink">&#949;</italic>
###xml 162 170 <span type="species:ncbi:9606">patients</span>
###xml 447 450 <span type="species:ncbi:10796?0.09130166563849476|species:ncbi:12211?0.07279457125231338">PPV</span>
###xml 2913 2916 <span type="species:ncbi:10796?0.09130166563849476|species:ncbi:12211?0.07279457125231338">PPV</span>
###xml 3374 3377 <span type="species:ncbi:10796?0.09130166563849476|species:ncbi:12211?0.07279457125231338">PPV</span>
This information is of importance in predicting the development of AD in early life. However, not all subjects with the epsilon4 allele develop AD, nor do all AD patients carry the epsilon4 allele. On the other hand, not all subjects are protected against AD by the epsilon2 and epsilon3 alleles. Therefore, it is important to estimate the probability that these allele carriers will develop AD. We found that the epsilon4/epsilon4 genotype had a PPV of 39.90% and an LR+ of 3.76 for AD. In other words, a subject carrying two epsilon4 alleles has a probability of 39.90% to develop AD. In contrast, a subject carrying one epsilon4 allele and one epsilon3 allele has a probability of 28.80% to develop AD, and a subject carrying one epsilon4 allele and one epsilon2 allele has a probability of 10.82% to develop AD. Based on the interpretation of LRs+ by Ebell [39], the presence of APOE alleles can only mildly change the risk for AD, despite a highly significant association with AD. This implies that APOE genotype testing can provide evidence on whether a subject may develop AD, but it is not sufficient as an independent screening or predictive test for the diagnosis of AD [44]. Additionally, we found the following order for both PPVs and LRs+ of APOE alleles and genotypes with respect to the diagnosis of AD: epsilon4/epsilon4 > epsilon4 > epsilon3/epsilon4 > epsilon3 > epsilon2/epsilon4 > epsilon3/epsilon3 > epsilon2 > epsilon2/epsilon3 (see Table 3). This order shows that: (1) epsilon4/epsilon4 > epsilon4, suggesting that the risk for AD increases with the number of epsilon4 alleles; (2) epsilon4 > epsilon3/epsilon4 and epsilon3/epsilon4 > AD population prevalence, suggesting that the epsilon3 allele reduces the risk for AD conveyed by the epsilon4 allele, but the protective effect of epsilon3 is weaker than the risk effect of epsilon4; (3) epsilon3/epsilon3 <epsilon3, suggesting that the protection against AD increases with the number of epsilon3 alleles; (4) epsilon3 > epsilon2/epsilon3 and epsilon2 > epsilon2/epsilon3, suggesting that the protective effect on AD risk for a genotype containing two protective alleles is greater than that for a genotype containing only one of the protective alleles; (5) epsilon3 > epsilon2 and epsilon3/epsilon3 > epsilon2/epsilon3, suggesting that the epsilon2 allele is a stronger protective factor for AD than the epsilon3 allele, which is reflected in their positions on the Y axis in the figure depicting the dose effect (Figure 2); and (6) epsilon3/epsilon4 > AD population prevalence, but epsilon2/epsilon3 <epsilon3/epsilon3 <epsilon3 < AD population prevalence, suggesting that without epsilon4, the epsilon3 allele and any genotypes containing the epsilon3 allele cannot increase risk for AD, that is, it is epsilon4, not epsilon3, that contributes to the increased risk of AD associated with the epsilon3/epsilon4 genotype. Similarly, the PPV for epsilon2/epsilon4 < AD population prevalence (i.e., a protective effect), but epsilon4/epsilon4 > epsilon4 > epsilon3/epsilon4 > AD population prevalence (i.e., a risk effect), suggesting that without epsilon2, the epsilon4 allele and any genotypes containing the epsilon4 allele (e.g., epsilon4/epsilon4 and epsilon3/epsilon4) do not have a protective effect; it is epsilon2, not epsilon4, that results in the epsilon2/epsilon4 genotype having a lower PPV. Taken together, the order of these effects suggests that epsilon4 is a dose-response risk factor for developing AD, epsilon2 is a dose-response protective factor, and epsilon3 is a relatively weaker dose-response protective factor. These findings are consistent with the results of our allelewise analyses, chi-square tests for trends, and logistic regression analyses.
###end p 65
###begin p 66
###xml 74 81 74 75 <italic xmlns:xlink="http://www.w3.org/1999/xlink">&#949;</italic>
###xml 107 114 101 102 <italic xmlns:xlink="http://www.w3.org/1999/xlink">&#949;</italic>
###xml 119 126 107 108 <italic xmlns:xlink="http://www.w3.org/1999/xlink">&#949;</italic>
###xml 177 182 159 164 <italic xmlns:xlink="http://www.w3.org/1999/xlink">APOE </italic>
###xml 281 283 263 265 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B45">45</xref>
###xml 339 346 321 322 <italic xmlns:xlink="http://www.w3.org/1999/xlink">&#949;</italic>
###xml 373 380 349 350 <italic xmlns:xlink="http://www.w3.org/1999/xlink">&#949;</italic>
###xml 386 393 356 357 <italic xmlns:xlink="http://www.w3.org/1999/xlink">&#949;</italic>
###xml 585 586 549 550 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B6">6</xref>
There has been debate about whether the presence of a "bad" allele (i.e., epsilon4) or of a "good" allele (epsilon2 or epsilon3), or both, contribute to the association between APOE and AD. The answer to this question is important for the development of specific therapies for AD [45]. Our results tend to show that both the "bad" allele (epsilon4) and the "good" alleles (epsilon2 and epsilon3) are involved in the risk for AD, consistent with codominant inheritance. These findings are supported by the evidence from studies on the neuropathological processes involved in AD [e.g., [6]].
###end p 66
###begin p 67
###xml 114 118 114 118 <italic xmlns:xlink="http://www.w3.org/1999/xlink">STH </italic>
###xml 180 185 180 185 <italic xmlns:xlink="http://www.w3.org/1999/xlink">APOE </italic>
###xml 189 193 189 193 <italic xmlns:xlink="http://www.w3.org/1999/xlink">STH </italic>
###xml 403 405 403 405 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B23">23</xref>
###xml 429 431 429 431 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B22">22</xref>
###xml 444 449 444 449 <italic xmlns:xlink="http://www.w3.org/1999/xlink">APOE </italic>
###xml 511 515 511 515 <italic xmlns:xlink="http://www.w3.org/1999/xlink">STH </italic>
Noting both the close interaction between the APOE and the tau proteins and the physical proximity of the Tau and STH genes, we investigated the correlation between effects of the APOE and STH gene polymorphisms. We found no significant interactive effect between these two genes either in cases or in controls. This finding was consistent with our regression analysis and the studies by Conrad et al. [23] and Peplonska et al. [22]. Thus, the APOE gene affects risk for AD through a pathway independent of the STH gene polymorphism we queried.
###end p 67
###begin p 68
###xml 38 42 38 42 <italic xmlns:xlink="http://www.w3.org/1999/xlink">STH </italic>
###xml 252 256 252 256 <italic xmlns:xlink="http://www.w3.org/1999/xlink">STH </italic>
###xml 335 337 335 337 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B23">23</xref>
###xml 708 710 708 710 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B25">25</xref>
###xml 763 765 763 765 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B27">27</xref>
###xml 815 817 815 817 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B28">28</xref>
###xml 887 889 887 889 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B29">29</xref>
###xml 943 945 943 945 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B22">22</xref>
###xml 1241 1243 1241 1243 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B22">22</xref>
###xml 1244 1246 1244 1246 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B25">25</xref>
###xml 1247 1249 1247 1249 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B27">27</xref>
###xml 1250 1252 1250 1252 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B29">29</xref>
###xml 1294 1296 1294 1296 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B24">24</xref>
###xml 1359 1363 1359 1363 <italic xmlns:xlink="http://www.w3.org/1999/xlink">STH </italic>
###xml 1514 1518 1514 1518 <italic xmlns:xlink="http://www.w3.org/1999/xlink">STH </italic>
We also found no associations between STH alleles and AD, even after adjusting for potential confounders, including age, sex, and family history. Neither the genotype analysis nor the gene-dose analysis showed any association. Our results suggest that STH may not be a risk gene for AD. The initial positive findings by Conrad et al. [23] may be attributable to sampling bias in the context of small sample sizes (51 AD cases; 30 healthy controls). Our sample size (286 AD cases; 197 healthy controls) is much larger than theirs. Moreover, our negative findings are in good agreement with many other studies, which also have much larger sample sizes (e.g., 499 AD cases and 402 controls by Verpillat et al. [25]; 225 AD cases and 144 controls by Streffer et al. [27]; 200 AD cases and 458 controls by Clark et al. [28]; 690 AD families, 903 AD cases and 320 controls by Oliveira et al. [29]; 100 AD cases and 100 controls by Peplonska et al. [22]). Additionally, the Q allele frequency (0.867) in controls in the initial study is similar to both controls and cases in our and the other negative studies; but the Q allele frequency (0.676) in AD cases is significantly lower than those in cases and controls in most of the published studies [22,25,27-29]. So far, there has been only one study [24] reporting a replicated positive finding between the genotype STH RR and AD (p = 0.04), but even this positive finding is only nominal and does not survive after Bonferroni correction. Therefore, we conclude that the STH gene Q7R variation does not play an important role in the pathology of AD.
###end p 68
###begin title 69
Competing interests
###end title 69
###begin p 70
The author(s) declare that they have no competing interests.
###end p 70
###begin title 71
Authors' contributions
###end title 71
###begin p 72
LZ designed the study, genotyped most of the subjects, analyzed and interpreted the data, and drafted the manuscript. CHVD collected the samples, participated in the design of the study, interpreted the data, and critically revised the manuscript. XL participated in designing the study, genotyping some subjects, analyzing and interpreting the data, and drafting the manuscript. HRK collected the samples, contributed to the interpretation, and made critical comments on the manuscript. BZY contributed to statistical analysis and data interpretation. JG obtained the funding, prepared the samples, supervised the study, interpreted the data, and made critical comments on the manuscript. All authors read and approved the final manuscript.
###end p 72
###begin title 73
Acknowledgements
###end title 73
###begin p 74
###xml 0 842 0 842 <italic xmlns:xlink="http://www.w3.org/1999/xlink">This work was supported in part by funds from the U.S. Department of Veterans Affairs (the VA Medical Research Program, and the VA Connecticut-Massachusetts Mental Illness Research, Education and Clinical Center [MIRECC], and the VA Research Enhancement Award Program [REAP] research center), National Institute of Mental Health (NIMH) grant K02-MH01387, National Institute on Drug Abuse (NIDA) grants R01-DA12849, R01-DA12690, and K24-DA15105, National Institute on Alcohol Abuse and Alcoholism (NIAAA) grants R01-AA016015-01, R01-AA11330, K08-AA13732 and K24-AA13736, National Center for Research Resources (NCRR) grant M01-RR06192 (University of Connecticut General Clinical Research Center), and Alcoholic Beverage Medical Research Foundation (ABMRF) grant award R06932 (X Luo). Ann Marie Lacobelle provided excellent technical assistance</italic>
This work was supported in part by funds from the U.S. Department of Veterans Affairs (the VA Medical Research Program, and the VA Connecticut-Massachusetts Mental Illness Research, Education and Clinical Center [MIRECC], and the VA Research Enhancement Award Program [REAP] research center), National Institute of Mental Health (NIMH) grant K02-MH01387, National Institute on Drug Abuse (NIDA) grants R01-DA12849, R01-DA12690, and K24-DA15105, National Institute on Alcohol Abuse and Alcoholism (NIAAA) grants R01-AA016015-01, R01-AA11330, K08-AA13732 and K24-AA13736, National Center for Research Resources (NCRR) grant M01-RR06192 (University of Connecticut General Clinical Research Center), and Alcoholic Beverage Medical Research Foundation (ABMRF) grant award R06932 (X Luo). Ann Marie Lacobelle provided excellent technical assistance.
###end p 74
###begin article-title 75
Amyloid plaque core protein in Alzheimer's disease and Down's syndrome
###end article-title 75
###begin article-title 76
###xml 11 15 11 12 <italic xmlns:xlink="http://www.w3.org/1999/xlink">&#946;</italic>
A study of beta-secretase cleaved Alzheimer amyloid precursor protein
###end article-title 76
###begin article-title 77
Pathogenesis of type III hyperlipoproteinemia (dysbetalipoproteinemia). Questions, quandaries, and paradoxes
###end article-title 77
###begin article-title 78
Alzheimer's disease: the cholesterol connection
###end article-title 78
###begin article-title 79
Apolipoprotein E immunoreactivity in cerebral amyloid deposits and neurofibrillary tangles in Alzheimer's disease and kuru plaque amyloid in Creutzfeldt-Jakob disease
###end article-title 79
###begin article-title 80
###xml 66 70 66 67 <italic xmlns:xlink="http://www.w3.org/1999/xlink">&#946;</italic>
SDS-Stable Complex Formation between Native Apolipoprotein E3 and beta-Amyloid Peptides
###end article-title 80
###begin article-title 81
###xml 36 39 36 37 <italic xmlns:xlink="http://www.w3.org/1999/xlink">&#964;</italic>
Microtubule-associated protein tau (tau) is a major antigenic component of paired helical filaments in Alzheimer's disease
###end article-title 81
###begin article-title 82
The tau H1 haplotype is associated and the risk of Alzheimer disease among African Americans, Whites, and Hispanics
###end article-title 82
###begin article-title 83
Tau gene polymorphisms and apolipoprotein E epsilon4 may interact to increase risk for Alzheimer's disease
###end article-title 83
###begin article-title 84
A polymorphism in the tau gene associated with risk for Alzheimer's disease
###end article-title 84
###begin article-title 85
The microtubule associated protein Tau gene and Alzheimer's disease-an association study and meta-analysis
###end article-title 85
###begin article-title 86
The tau locus is not significantly associated with pathologically confirmed sporadic Parkinson's disease
###end article-title 86
###begin article-title 87
Proposed nomenclature of apoE isoproteins, apoE genotypes, and phenotypes
###end article-title 87
###begin article-title 88
Apolipoprotein E genotype, Alzheimer's pathologies and related gene expression in the aged population
###end article-title 88
###begin article-title 89
Genetic association between the apolipoprotein E (ApoE) gene alleles and various forms of Alzheimer's disease
###end article-title 89
###begin article-title 90
Interaction of the H63D mutation in the hemochromatosis gene with the apolipoprotein E epsilon 4 allele modulates age at onset of Alzheimer's disease
###end article-title 90
###begin article-title 91
A Japanese family with familial Alzheimer's disease associated with presenilin 1 mutation: relationship between younger age of onset and ApoE gene polymorphism
###end article-title 91
###begin article-title 92
Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families
###end article-title 92
###begin article-title 93
###xml 77 85 <span type="species:ncbi:9606">patients</span>
Apolipoprotein E and age at onset of Alzheimer's disease in African American patients
###end article-title 93
###begin article-title 94
Accelerated hippocampal atrophy in Alzheimer's disease with apolipoprotein E epsilon4 allele
###end article-title 94
###begin article-title 95
Strong association of the Saitohin gene Q7 variant with progressive supranuclear palsy
###end article-title 95
###begin article-title 96
Strong association between Saitohin gene polymorphism and tau haplotype in the Polish population
###end article-title 96
###begin article-title 97
A polymorphic gene nested within an intron of the tau gene: implications for Alzheimer's disease
###end article-title 97
###begin article-title 98
Age-dependent association between the Q7R polymorphism in the Saitohin gene and sporadic Alzheimer's disease
###end article-title 98
###begin article-title 99
Association between the extended tau haplotype and frontotemporal dementia
###end article-title 99
###begin article-title 100
###xml 55 63 <span type="species:ncbi:9606">patients</span>
Mutation screening of the MAPT and STH genes in Polish patients with clinically diagnosed frontotemporal dementia
###end article-title 100
###begin article-title 101
Saitohin gene is not associated with Alzheimer's disease
###end article-title 101
###begin article-title 102
The Saitohin 'Q7R' polymorphism and tau haplotype in multi-ethnic Alzheimer disease and Parkinson's disease cohorts
###end article-title 102
###begin article-title 103
The Q7R Saitohin gene polymorphism is not associated with Alzheimer disease
###end article-title 103
###begin article-title 104
###xml 128 133 <span type="species:ncbi:9606">Human</span>
Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services task force on Alzheimer's disease
###end article-title 104
###begin article-title 105
Familial Alzheimer's disease: a prevalent disorder with specific clinical features
###end article-title 105
###begin article-title 106
Reliability of the family history method in genetic studies of Alzheimer's disease and related dementias
###end article-title 106
###begin article-title 107
Schedule for Affective Disorders and Schizophrenia: Lifetime version
###end article-title 107
###begin article-title 108
###xml 75 83 <span type="species:ncbi:9606">patients</span>
"Mini-mental state". A practical method for grading the cognitive state of patients for the clinician
###end article-title 108
###begin article-title 109
Apolipoprotein E: risk factor for Alzheimer disease
###end article-title 109
###begin article-title 110
A Simple sequentially rejective multiple test procedure
###end article-title 110
###begin article-title 111
Prevalence of Alzheimer's disease in a retirement community
###end article-title 111
###begin article-title 112
True Epistat Version 6.0
###end article-title 112
###begin article-title 113
###xml 119 127 <span type="species:ncbi:9606">patients</span>
Apolipoprotein-E genotype in normal aging, age-associated memory impairment, Alzheimer's disease and vascular dementia patients
###end article-title 113
###begin article-title 114
Evidence for an interaction between apolipoprotein E genotype, gender, and Alzheimer disease
###end article-title 114
###begin article-title 115
Association of apolipoprotein E polymorphism with plasma lipids and Alzheimer's disease in a Southern Brazilian population
###end article-title 115
###begin article-title 116
Vascular risk and genetics of Sporadic Late-Onset Alzheimer's Disease
###end article-title 116
###begin article-title 117
ApoE: Is it the absence of good or the presence of bad?
###end article-title 117

